32 related articles for article (PubMed ID: 16360199)
1. Efficacy and Safety of Immunotherapy for Cervical Cancer-A Systematic Review of Clinical Trials.
Schmidt MW; Battista MJ; Schmidt M; Garcia M; Siepmann T; Hasenburg A; Anic K
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053603
[TBL] [Abstract][Full Text] [Related]
2. Combined use of preoperative lymphocyte counts and the post/preoperative lymphocyte count ratio as a prognostic marker of recurrence after curative resection of stage II colon cancer.
Shinji S; Ueda Y; Yamada T; Koizumi M; Yokoyama Y; Takahashi G; Hotta M; Iwai T; Hara K; Takeda K; Okusa M; Kan H; Uchida E
Oncotarget; 2018 Jan; 9(2):2553-2564. PubMed ID: 29416791
[TBL] [Abstract][Full Text] [Related]
3. Possible role of thymidine phosphorylase in gynecological tumors as an individualized treatment strategy.
Shida M; Yasuda M; Fujita M; Miyazawa M; Kajiwara H; Hirasawa T; Ikeda M; Matsui N; Muramatsu T; Mikami M
Oncol Lett; 2016 Nov; 12(5):3215-3223. PubMed ID: 27899985
[TBL] [Abstract][Full Text] [Related]
4. Major clinical research advances in gynecologic cancer in 2014.
Suh DH; Lee KH; Kim K; Kang S; Kim JW
J Gynecol Oncol; 2015 Apr; 26(2):156-67. PubMed ID: 25872896
[TBL] [Abstract][Full Text] [Related]
5. Updates in systemic treatment for metastatic cervical cancer.
Chao A; Lin CT; Lai CH
Curr Treat Options Oncol; 2014 Mar; 15(1):1-13. PubMed ID: 24429797
[TBL] [Abstract][Full Text] [Related]
6. Zn- and Mg- containing tricalcium phosphates-based adjuvants for cancer immunotherapy.
Wang X; Li X; Onuma K; Sogo Y; Ohno T; Ito A
Sci Rep; 2013; 3():2203. PubMed ID: 23857555
[TBL] [Abstract][Full Text] [Related]
7. IP(3) receptor antagonist, 2-APB, attenuates cisplatin induced Ca2+-influx in HeLa-S3 cells and prevents activation of calpain and induction of apoptosis.
Splettstoesser F; Florea AM; Büsselberg D
Br J Pharmacol; 2007 Aug; 151(8):1176-86. PubMed ID: 17592515
[TBL] [Abstract][Full Text] [Related]
8. Potential for use of amifostine in cervical cancer.
Small W
Semin Oncol; 2002 Dec; 29(6 Suppl 19):34-7. PubMed ID: 12577241
[TBL] [Abstract][Full Text] [Related]
9. Carcinoma of the uterine cervix: current status and future directions.
Thigpen T; Vance RB; Khansur T
Semin Oncol; 1994 Apr; 21(2 Suppl 2):43-54; quiz 55, 58. PubMed ID: 8202720
[TBL] [Abstract][Full Text] [Related]
10. Phase III double-blind randomized trial of radiation therapy for stage IIIb cervical cancer in combination with low- or high-dose Z-100: treatment with immunomodulator, more is not better.
Noda K; Ohashi Y; Sugimori H; Ozaki M; Niibe H; Ogita S; Kohno I; Hasegawa K; Kikuchi Y; Takegawa Y; Fujii S; Tanaka K; Ochiai K; Kita M; Fujiwara K
Gynecol Oncol; 2006 Jun; 101(3):455-63. PubMed ID: 16360199
[TBL] [Abstract][Full Text] [Related]
11. Randomized phase II study of immunomodulator Z-100 in patients with stage IIIB cervical cancer with radiation therapy.
Noda K; Ohashi Y; Okada H; Ogita S; Ozaki M; Kikuchi Y; Takegawa Y; Niibe H; Fujii S; Horiuchi J; Morita K; Hashimoto S; Fujiwara K
Jpn J Clin Oncol; 2006 Sep; 36(9):570-7. PubMed ID: 16926224
[TBL] [Abstract][Full Text] [Related]
12. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
Eifel PJ; Winter K; Morris M; Levenback C; Grigsby PW; Cooper J; Rotman M; Gershenson D; Mutch DG
J Clin Oncol; 2004 Mar; 22(5):872-80. PubMed ID: 14990643
[TBL] [Abstract][Full Text] [Related]
13. Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study.
Sugiyama T; Fujiwara K; Ohashi Y; Yokota H; Hatae M; Ohno T; Nagai Y; Mitsuhashi N; Ochiai K; Noda K
Ann Oncol; 2014 May; 25(5):1011-7. PubMed ID: 24569914
[TBL] [Abstract][Full Text] [Related]
14. A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
Gatcliffe TA; Tewari KS; Shah A; Brewster WR; Burger RA; Kuo JV; Monk BJ
Gynecol Oncol; 2009 Jan; 112(1):85-9. PubMed ID: 18977518
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
